Utility of the Nonabsorbed (<0.4%) Antibiotic Rifaximin in Gastroenterology and Hepatology

Por Su, Chinyu G., Aberra, Faten, Lichtenstein, Gary R.
Publicado no Gastroenterol Hepatol (N Y) (2006)

A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response

Por Su, Chinyu G., Wen, Xiaoming, Bailey, Shannon T., Jiang, Wen, Rangwala, Shamina M., Keilbaugh, Sue A., Flanigan, Anne, Murthy, Sreekant, Lazar, Mitchell A., Wu, Gary D.
Publicado em 1999